DNTH
NASDAQ · Biotechnology
Dianthus Therapeutics Inc
$90.49
+4.46 (+5.18%)
Financial Highlights (FY 2026)
Revenue
2.89M
Net Income
-230,515,885
Gross Margin
—
Profit Margin
-7,973.3%
Rev Growth
—
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | 59.5% | 59.5% | 59.5% |
| Operating Margin | -8,739.3% | -7.7% | -8.7% | -8.9% |
| Profit Margin | -7,973.3% | -10.6% | -9.9% | -7.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 2.89M | 305.72M | 270.76M | 300.06M |
| Gross Profit | — | 182.00M | 161.18M | 178.62M |
| Operating Income | -252,556,351 | -23,432,131 | -23,480,152 | -26,710,232 |
| Net Income | -230,515,885 | -32,339,215 | -26,813,974 | -23,242,376 |
| Gross Margin | — | 59.5% | 59.5% | 59.5% |
| Operating Margin | -8,739.3% | -7.7% | -8.7% | -8.9% |
| Profit Margin | -7,973.3% | -10.6% | -9.9% | -7.8% |
| Rev Growth | — | +9.7% | -3.3% | +12.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 723.10M | 898.19M | 900.24M |
| Total Equity | — | 1.27B | 1.08B | 1.09B |
| D/E Ratio | — | 0.57 | 0.83 | 0.83 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -252,505,292 | -32,605,970 | -27,281,394 | -31,596,299 |
| Free Cash Flow | — | -20,890,110 | -21,520,158 | -23,925,877 |